Psilocybin and Cognitive Function: What Happens to the Brain

Psilocybin produces significant acute effects on cognition — some degrading normal performance, others enhancing specific functions. Understanding what actually happens to cognitive performance, and what persists after the acute phase, is important for anyone considering psilocybin in a therapeutic context.

Acute Cognitive Effects (During the Session)

During the peak of a psilocybin experience, conventional cognitive performance is significantly impaired. This is by design and is not a concern for therapeutic use, where the session is not a time for cognitive tasks.

Working memory: Reduced during peak effects. The capacity to hold and manipulate information in short-term memory decreases with dose. This is partly why psilocybin sessions feel timeless — the normal cognitive architecture of tracking time and sequence is disrupted.

Attention: Focused, sustained attention becomes difficult. The mind moves through unusual associations, memories, and perceptions. This is the therapeutic terrain, not a problem to be solved.

Language and verbal fluency: Often reduced. Many people find it difficult to speak coherently during peak effects, which is why non-verbal communication (the music, the supportive presence of a facilitator) is central to session design.

Pattern recognition and creativity: Enhanced in some cognitive testing paradigms. Psilocybin increases "associative thinking" — the ability to connect ideas across domains — in ways measured by creativity tasks. This is one mechanism behind the reports of insight and creative breakthrough during sessions.

Sub-Acute Cognitive Effects (Hours to Days After)

The period immediately following a psilocybin session is characterized by what many describe as a cognitive "afterglow." Research suggests this is partly biological:

Cognitive flexibility: Enhanced in the days following psilocybin sessions. Measures of set-shifting (the ability to switch between different cognitive frameworks) show improvement over baseline. This is the substrate for the integration of new perspectives that characterizes successful therapeutic outcomes.

Open-mindedness and reduced rigidity: Research participants consistently score higher on measures of psychological flexibility and openness in the weeks following psilocybin treatment. These are not just subjective feelings — they correlate with observable changes in belief updating and perspective-taking.

Emotional processing: Memory retrieval for emotionally valenced material shows changes post-treatment, with reduced negative valence bias. Depressed patients who remember past events with predominantly negative affect often show more balanced recall after psilocybin.

The Neuroplasticity Window

The most important cognitive consequence of psilocybin for therapeutic purposes is the neuroplasticity window — the period of enhanced synaptic plasticity that follows a session.

BDNF upregulation: Psilocybin reliably increases BDNF (Brain-Derived Neurotrophic Factor), a protein critical to synaptic formation, neural survival, and the biological substrate of learning. BDNF is reduced in depression, anxiety, and PTSD. Increasing it creates conditions in which new learning is more readily encoded.

Dendritic spine growth: Animal studies (Shao et al., 2021, in Neuron) demonstrate that psilocybin produces rapid increases in dendritic spine density in the prefrontal cortex — lasting weeks after a single dose. These structural changes represent new synaptic connections. Whether exactly the same occurs in humans at clinical doses is not yet confirmed in human histology, but functional imaging suggests analogous changes.

Duration of the window: The plasticity window is not indefinitely open. Evidence suggests it diminishes significantly within 2–4 weeks of the session. This is why integration therapy — including new behaviors, new associations, and new relational patterns — is most effective when begun immediately after the session.

Long-Term Cognitive Effects

Does repeated or occasional therapeutic use of psilocybin produce lasting cognitive deficits? The research to date suggests no.

Observational studies of long-term users: Multiple studies examining people with extensive psilocybin experience find no evidence of cognitive impairment compared to controls. A landmark 2013 study (Krebs and Johansen, PLoS ONE) examining over 21,000 psychedelic users found no association between lifetime psychedelic use and cognitive deficits, mental health treatment, or suicidality.

Clinical trial follow-up data: Participants in clinical trials at Hopkins, NYU, and Imperial College London have been followed for up to 12 months after psilocybin treatment and show no evidence of cognitive decline.

Who Should Exercise Caution

Cognitive risks are not uniform across all users:

Older adults: Mild cognitive impairment (MCI) is a relative contraindication; psilocybin's acute cognitive effects may be more disorienting in this population
Those with pre-existing cognitive challenges: ADHD, traumatic brain injury, processing speed deficits
Those requiring cognitive precision immediately post-session: Arrange time off from demanding cognitive work for 24–48 hours after a session